uniQure N.V. reported its financial results for the second quarter of 2025 on July 29, 2025, alongside updates on its clinical programs and strategic developments. The company's cash, cash equivalents, and current investment securities stood at $377.0 million as of June 30, 2025, which is expected to fund operations into the second half of 2027.
For Q2 2025, revenue decreased to $5.3 million from $11.1 million in Q2 2024, primarily due to reduced collaboration and contract manufacturing revenue following the divestiture of the Lexington facility. However, the net loss for the quarter narrowed to $37.7 million, or $0.69 per share, an improvement from a $56.3 million net loss, or $1.16 per share, in Q2 2024. This was significantly aided by an increase in net foreign currency gains, resulting in $6.6 million in other non-operating income.
Research and development expenses increased slightly to $35.4 million from $33.7 million in the prior year, driven by increased external program spending and contingent consideration, partially offset by reduced employee and facility expenses. Selling, general, and administrative expenses decreased to $13.5 million from $15.8 million, reflecting cost control efforts.
On the clinical front, uniQure achieved alignment with the FDA on the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) requirements for AMT-130, supporting a planned Biologics License Application (BLA) submission in the first quarter of 2026. Topline three-year data for AMT-130 are expected in September 2025. Additionally, a case study from the first patient treated with AMT-260 for refractory mesial temporal lobe epilepsy showed a 92% seizure reduction with no serious adverse events through the first five months of follow-up. The company also announced the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, signaling commercialization readiness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.